Decreased phosphorylation of STAT-1, STAT-4 and cytokine release in MDR-TB patients with primary resistance

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 9, 2008, Pages 1071-1076

  Kim, H J ^a,b   Chung, D H ^c   Kim, M J ^a   Jang, J H ^b   Kim, Y W ^a   Han, S K ^a   Shim, Y S ^a   Yim, J J ^a,d  

^a Seoul National University College of Medicine   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

IFN ; IL 12; MDR TB; pSTAT 1; pSTAT 4; TNF

Indexed keywords

BACTERIUM LYSATE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P40; STAT1 PROTEIN; STAT4 PROTEIN; TUBERCULIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BACTERIAL CELL; BACTERIUM CULTURE; CELL CULTURE; CELL STIMULATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; LUNG TUBERCULOSIS; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUPERNATANT;

ADOLESCENT; ADULT; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PHOSPHORYLATION; STAT1 TRANSCRIPTION FACTOR; STAT4 TRANSCRIPTION FACTOR; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 51149095389     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kang Y A, Choi Y J, Cho Y J, et al. Cost of treatment for multidrug-resistant tuberculosis in South Korea. Respirology 2006; 11:793-798.
2. Iseman M D. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-791.
3. Dye C, Espinal M A, Watt C J, et al. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185: 1197-1202.
4. Goble M, Iseman M D, Madsen L A, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
5. Kim H J, Hong Y P, Kim S J, et al. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis 2001; 5: 1129-1136.
6. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
7. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.
8. Kim H R, Hwang S S, Kim H J, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295.
9. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
10. Kim H J, Kang C H, Kim Y T, et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J 2006; 28: 576-580.
11. Rosenzweig S D, Holland S M. Defects in the interferon-gamma and interleukin-12 pathways. Immunol Rev 2005; 203: 38-47.
12. World Health Organization. Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210 (Rev. 1). Geneva, Switzerland: WHO, 1997.
13. Newport M J, Huxley C M, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335: 1941-1949.
14. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med 1996; 335: 1956-1961.
15. Dorman S E, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004; 364: 2113-2121.
16. Dorman S E, Holland S M. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J Clin Invest 1998; 101: 2364-2369.
17. Rosenzweig S D, Dorman S E, Uzel G, et al. A novel mutation in IFN-gamma receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states. J Immunol 2004; 173: 4000-4008.
18. Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998; 280: 1432-1435.
19. de Jong R, Altare F, Haagen I A, et al. Severe mycobacterial and salmonella infections in interleukin-12 receptor-deficient patients. Science 1998; 280: 1435-1438.
20. Picard C, Fieschi C, Altare F, et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet 2002; 70: 336-348.
21. Dupuis S, Jouanguy E, Al-Hajjar S, et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 2003; 33: 388-391.
22. Dupuis S, Dargemont C, Fieschi C, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001; 293: 300-303.
23. Chapgier A, Wynn R F, Jouanguy E, et al. Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo. J Immunol 2006; 176: 5078-5083.
24. Sofia M, Maniscalco M, Honore N, et al. Familial outbreak of disseminated multidrug-resistant tuberculosis and meningitis. Int J Tuberc Lung Dis 2001; 5: 551-558.